Introduction Nitrosamine Risk in Drug-Drug Combination Products has emerged as a significant toxicological challenge because combining multiple active pharmaceutical ingredients […]
Introduction Nitrosamines from Excipients primarily arise when trace levels of nitrite impurities present in inactive formulation components react with susceptible
Introduction Nitrosamine Control Strategy Development Services offer a comprehensive, science-driven framework for identifying, quantifying, and controlling mutagenic N-nitroso impurities throughout
Introduction: Implementation of Nitrosamine Testing for Injectable Drug Products is a critical safety and regulatory requirement because parenteral drug products
Introduction A formal nitrosamine risk assessment should begin during the preclinical stage of development, specifically during candidate selection and the
When Should You Start Nitrosamine Risk Assessment in Your Drug Development Program? Read More »
The Critical Role of Nitrosamine Testing for a Metformin Generic Nitrosamine Testing for a Metformin Generic is a critical regulatory
Assessing the chemical safety of human drug products requires a thorough understanding of potential mutagenic and carcinogenic impurities that fall
Introduction: Nitrosamine impurities are among the most scrutinized safety concerns in modern pharmaceutical development, and no NDA or BLA submission
Nitrosamine Risk Assessment and Testing Services for NDA and BLA Submissions Read More »
Introduction: Nitrosamine Testing Inhalation Drug Products MDI DPI Nasal Spray has become a critical focus area for pharmaceutical manufacturers after
Nitrosamine Testing for Inhalation Drug Products: MDIs, DPIs, and Nasal Sprays Read More »
Introduction: Why Conventional Mutagenicity Models Are Inadequate for NDSRIs The regulatory complexity associated with N-Nitrosamine Drug Substance-Related Impurities (NDSRIs) extends
